摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-Dimethylcarbamoyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid ethyl ester | 86610-89-1

中文名称
——
中文别名
——
英文名称
9-Dimethylcarbamoyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid ethyl ester
英文别名
Ethyl 9-(dimethylcarbamoyl)-6-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-3-carboxylate
9-Dimethylcarbamoyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid ethyl ester化学式
CAS
86610-89-1
化学式
C15H21N3O4
mdl
——
分子量
307.349
InChiKey
BACGLSCSGLXGMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    79.3
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    9-Dimethylcarbamoyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid ethyl ester氢氧化钾 作用下, 以 乙醇 为溶剂, 反应 20.0h, 生成 Potassium; 9-dimethylcarbamoyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylate
    参考文献:
    名称:
    氮桥头化合物。38.新型抗过敏的4H-吡啶并[1,2-a]嘧啶-4-酮。3。
    摘要:
    6-甲基-4-氧代-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-3-羧酸(4)对大鼠原尿被动皮肤过敏反应的弱抗过敏活性通过将适当的官能团引入到吡啶并嘧啶环的9位上,可以增强α-β。最具活性的9-取代的吡啶并嘧啶羧酸在9位上含有肟,苯氨基或(苯基氨基)硫代氧甲基。9-苯基羧酰胺基和9-苯基肼基部分可被视为吡啶并嘧啶酮系列中的生物等排基团。在9-(芳基氨基)二氢吡啶并嘧啶系列中,结构-活性关系研究揭示了与9-(芳基肼基)四氢吡啶并嘧啶类似的关系。生物学活性归因于6S对映异构体。9位的单取代芳基氨基部分对于静脉内活性是必需的。活性最高的化合物9-[((3-乙酰基苯基)氨基] -6-甲基-4-氧代-6,7,8,9-四氢-4H-吡啶基[1,2-a]嘧啶-3-羧酸(40)在被动性皮肤过敏反应(PCA)测试中的活性是参考铬酸葡萄糖酸钠(DSCG)的三倍。
    DOI:
    10.1021/jm00364a025
  • 作为产物:
    参考文献:
    名称:
    Structural studies on 6-methyl-9-carbamoyl-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones by1H,13C and15N NMR spectroscopy
    摘要:
    AbstractSeveral 6‐methyl‐9‐carbamoyltetrahydro‐4H‐pyrido[1,2‐α]pyrimidin‐4‐ones have been prepared using phosgene iminium chloride. These compounds can exist in equilibrium as the cis (3A) imine ⇌ (3B) enamine ⇌ trans (3C) imine. 1H, 13C and 15N NMR prove that the cis‐ and trans‐imine isomers are predominant in the equilibrium. 1H NMR data reveal that the share of the 3B enamine form is negligible at measurable concentrations. The isomeric ratio 3A:3C is time dependent and can be monitored by measuring the CH3C‐6 and (CH3)2N signals. The 13C NMR data show that doublets in the range 42–45 ppm for C‐9 are only compatible with the imine forms 3A and 3C. The SCS values of the CH3C‐6 and OCN(CH3)2 groups were calculated and used for identification of the cis and trans isomers. 15N NMR data show that the N‐1 chemical shift of the imine is approximately − 140 ppm for compound 3, whereas that of a fixed enamine is around − 267.8. This provides additional support for the predominance of the imine tautomers in the equilibrium 3A ⇌ 3B ⇌ 3C. 15N data allow the stereoisomers 3A and 3C to be distinguished.
    DOI:
    10.1002/mrc.1270200408
点击查看最新优质反应信息

文献信息

  • Structural studies on 6-methyl-9-carbamoyl-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones by1H,13C and15N NMR spectroscopy
    作者:Gábor Tóth、Carlos de La Cruz、István Bitter、István Hermecz、Béla Pete、Zoltán Mészáros
    DOI:10.1002/mrc.1270200408
    日期:1982.12
    AbstractSeveral 6‐methyl‐9‐carbamoyltetrahydro‐4H‐pyrido[1,2‐α]pyrimidin‐4‐ones have been prepared using phosgene iminium chloride. These compounds can exist in equilibrium as the cis (3A) imine ⇌ (3B) enamine ⇌ trans (3C) imine. 1H, 13C and 15N NMR prove that the cis‐ and trans‐imine isomers are predominant in the equilibrium. 1H NMR data reveal that the share of the 3B enamine form is negligible at measurable concentrations. The isomeric ratio 3A:3C is time dependent and can be monitored by measuring the CH3C‐6 and (CH3)2N signals. The 13C NMR data show that doublets in the range 42–45 ppm for C‐9 are only compatible with the imine forms 3A and 3C. The SCS values of the CH3C‐6 and OCN(CH3)2 groups were calculated and used for identification of the cis and trans isomers. 15N NMR data show that the N‐1 chemical shift of the imine is approximately − 140 ppm for compound 3, whereas that of a fixed enamine is around − 267.8. This provides additional support for the predominance of the imine tautomers in the equilibrium 3A ⇌ 3B ⇌ 3C. 15N data allow the stereoisomers 3A and 3C to be distinguished.
  • Nitrogen bridgehead compounds. 38. New antiallergic 4H-pyrido[1,2-a]pyrimidin-4-ones. 3
    作者:Istvan Hermecz、Tibor Breining、Lelle Vasvari-Debreczy、Agnes Horvath、Zoltan Meszaros、Istvan Bitter、Christine DeVos、Ludovic Rodriguez
    DOI:10.1021/jm00364a025
    日期:1983.10
    The weak antiallergic activity of 6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid (4) on the rat reaginic passive cutaneous anaphylaxis test was enhanced by the introduction of appropriate functional groups into position 9 of the pyridopyrimidine ring. The most active 9-substituted pyridopyrimidinecarboxylic acids contained an oxime, a phenylamino, or a (phenylamino)thioxomethyl
    6-甲基-4-氧代-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-3-羧酸(4)对大鼠原尿被动皮肤过敏反应的弱抗过敏活性通过将适当的官能团引入到吡啶并嘧啶环的9位上,可以增强α-β。最具活性的9-取代的吡啶并嘧啶羧酸在9位上含有肟,苯氨基或(苯基氨基)硫代氧甲基。9-苯基羧酰胺基和9-苯基肼基部分可被视为吡啶并嘧啶酮系列中的生物等排基团。在9-(芳基氨基)二氢吡啶并嘧啶系列中,结构-活性关系研究揭示了与9-(芳基肼基)四氢吡啶并嘧啶类似的关系。生物学活性归因于6S对映异构体。9位的单取代芳基氨基部分对于静脉内活性是必需的。活性最高的化合物9-[((3-乙酰基苯基)氨基] -6-甲基-4-氧代-6,7,8,9-四氢-4H-吡啶基[1,2-a]嘧啶-3-羧酸(40)在被动性皮肤过敏反应(PCA)测试中的活性是参考铬酸葡萄糖酸钠(DSCG)的三倍。
查看更多

同类化合物

阿昔替酯 螺喹唑啉 苯并[g][1,2,3]三唑并[4',5':5,6]吡啶并[2,1-b]喹唑啉-13(2H)-酮 脱氢利培酮 盐酸曲林菌素 甲硫利马唑 甲基8-乙基-2-甲氧基-5-氧代-5,8-二氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基8-乙基-2-(甲硫基)-5-氧代-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基2-乙氧基-8-乙基-5-氧代-吡啶并[6,5-d]嘧啶-6-羧酸酯 溴他替尼 泮托拉唑杂质DF 氨甲酸,[(2R,3E)-2-羟基-3-戊烯基]-,1,1-二甲基乙基酯(9CI) 柱孢藻毒素 曲美替尼 曲美替尼 曲喹辛 帕潘立酮棕榈酸酯 帕潘立酮杂质7 帕潘立酮杂质 帕潘立酮杂质 帕潘立酮 帕泊昔布杂质117 帕利哌酮十四酸酯 帕利哌酮N-氧化物 布喹特林 巴马斯汀 奥卡哌酮 多夸司特 吡曲克辛 吡嘧司特钾 吡嘧司特 吡啶并[4,3-d]嘧啶-4(1H)-酮,4,5,6,7-四氢-6-甲基-2-苯基- 吡啶并[4,3-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,4-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,2-d]嘧啶-4(3H)-酮,3-甲基-2-(甲基氨基)- 吡啶并[3,2-d]嘧啶-4(3H)-酮 吡啶并[3,2-d]嘧啶-4(1H)-酮,2,3-二氢-3-(2-羟基苯基)-2-硫代- 吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮 吡啶并[2,3-d]嘧啶-7(8h)-酮,2,6-二溴-8-环戊基-5-甲基- 吡啶并[2,3-d]嘧啶-7(8H)-酮 吡啶并[2,3-d]嘧啶-7(1H)-酮,4-氨基-5,6-二氢-5-甲基- 吡啶并[2,3-d]嘧啶-6-羧酸,1-(2,4-二甲基苯基)-1,4-二氢-2,7-二甲基-4-羰基-,酰肼 吡啶并[2,3-d]嘧啶-4(3H)-酮,5,7-二甲基-2-(甲硫基)-3-苯基- 吡啶并[2,3-d]嘧啶-4(3H)-酮 吡啶并[2,3-d]嘧啶-4(1H)-酮,2,3-二氢-1-(4-甲基苯基)-2-硫代- 吡啶并[2,3-d]嘧啶-2-胺 吡啶并[2,3-d]嘧啶 吡啶并[2,3-D]嘧啶-4-胺 吡啶并[2,3-D]嘧啶-2,4,7(1H,3H,8H)-三酮 吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮